[CAS NO. 193153-04-7] Otamixaban

Name: Otamixaban
Brand: Arctom Scientific
SKU: AS906406

Ships within Stock Price Qty Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [193153-04-7]

Fulfillment

Catalog

AS906406

Brand

Arctom Scientific

CAS

193153-04-7

DESCRIPTION [193153-04-7]

Overview

MDL	MFCD11100277
Molecular Weight	446.50
Molecular Formula	C25H26N4O4
SMILES	N=C(C1=CC=CC(C[C@@H](C(OC)=O)[C@H](NC(C2=CC=C(C=C2)C3=CC=[N+]([O-])C=C3)=O)C)=C1)N

For research use only. We do not sell to patients.

Summary

Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. IC50 value: Target: Factor Xa Otamixaban is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. In vivo experiments have demonstrated that Otamixaban is highly efficacious in rodent, canine and porcine models of thrombosis. In addition, recent clinical findings indicate that Otamixaban is efficacious, safe and well tolerated in humans and therefore has considerable potential for the treatment of acute coronary syndrome. This review article chronicles the discovery and pre-clinical data surrounding the fXa inhibitor Otamixaban as well as the recent clinical findings in humans.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00317395	Sanofi	Coronary Disease	June 2006	Phase 2
NCT00133731	Sanofi	Angioplasty, Transluminal, Percutaneous Coronary	September 2004	Phase 2
NCT01126086	Sanofi	Hepatic Impairment	May 2010	Phase 1
NCT01120314	Sanofi	Renal Impairment	April 2010	Phase 1
NCT01076764	Sanofi	Acute Coronary Syndrome	April 2010	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 111.98 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2396 mL	11.1982 mL	22.3964 mL
5 mM	0.4479 mL	2.2396 mL	4.4793 mL
10 mM	0.2240 mL	1.1198 mL	2.2396 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.75 mg/mL (6.16 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.75 mg/mL (6.16 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.75 mg/mL (6.16 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Benzenepropanoic acid, 3-(aminoiminomethyl)-α-[(1R)-1-[[4-(1-oxido-4-pyridinyl)benzoyl]amino]ethyl]-, methyl ester, (αR)-

Benzenepropanoic acid, 3-(aminoiminomethyl)-α-[1-[[4-(1-oxido-4-pyridinyl)benzoyl]amino]ethyl]-, methyl ester, [R-(R*,R*)]-

FXV 673

Methyl (2R,3R)-2-[3-amidinobenzyl]-3-[[4-(1-oxido-4-pyridinyl)benzoyl]amino]butanoate

Otamixaban